Cyclosporine A reduction and withdrawal in liver transplantation: a risk-benefit analysis.
Golling
M
M
Department of Surgery, University of Heidelberg, Germany.
Frankenberg
M V
MV
Hofmann
W J
WJ
Lohse
A
A
Herfarth
C
C
Otto
G
G
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001794:Blood Pressure; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005951:Glucose Tolerance Test; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D018570:Risk Assessment; D013997:Time Factors; D005723:gamma-Glutamyltransferase / Q000097:blood
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D003404:Creatinine; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase